Rizol is specifically used to help manage the overall course of the disease for patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). This specialized, chronic treatment is applied across domains where additional symptomatic support is needed.

The medication is commonly used to help with the long-term management of this condition, also known as Lou Gehrig's disease. Its primary role is applied in addressing the progression of the condition. Indications are centered on the chronic care of adult patients with the sporadic or familial form of ALS, who are seeking supportive relief.

Supporting Motor and Functional Stability

The treatment is applied when appropriate for managing symptoms that interfere with daily functioning in key areas, including muscle strength, mobility, and bulbar function (speech and swallowing). Rizol is commonly used to help with managing the functional stability of breathing, which is a key area of concern in ALS. This intervention assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.

---

Quick Fact: Supportive Care for ALS

Property	Description
Therapeutic Focus	Used for the management of Amyotrophic Lateral Sclerosis (ALS).
Symptom Focus	Supports management of functional decline.
Context	Applied as long-term supportive care for adult patients.
Area of Concern	Addressing progressive functional decline and respiratory concerns.

---

Regulatory References

1. Rilutek | European Medicines Agency (EMA)

Official Eligibility Profile for Rizol (Riluzole)

According to regulatory documents, Rizol is approved only for the treatment of adult patients (18 years and older) diagnosed with Amyotrophic Lateral Sclerosis (ALS).

Who Must Not Use Rizol (Contraindications)

Use is formally contraindicated in several specific populations, meaning the medicine must not be taken. These absolute exclusions include individuals with a confirmed history of severe hypersensitivity reactions to Riluzole or any of its components. Furthermore, Rizol is contraindicated in patients with existing hepatic disease or baseline serum transaminase levels greater than three times the upper limit of normal.

Status	Regulatory Classification
Pregnancy	Contraindicated
Lactation/Breastfeeding	Contraindicated

Populations with Restricted or Limited Use

Use is not recommended for the pediatric population (under 18 years) because safety and effectiveness have not been established. Patients with impaired renal function are also not recommended for treatment due to a lack of repeated dose studies in this group. Patients with mild hepatic impairment require treatment with caution and close monitoring.

Interactions with other medicines and products

Regulatory documentation outlines specific interaction patterns for Rizol (Riluzole), primarily involving its metabolism and potential additive toxicity. The principal pharmacokinetic interaction stems from Rizol's metabolism by the CYP1A2 enzyme, which is documented as the main isozyme responsible for its initial breakdown. Consequently, co-administration with strong or moderate CYP1A2 inhibitors (e.g., Fluvoxamine, Ciprofloxacin) is expected to increase Riluzole plasma exposure.

Conversely, co-administration with strong or moderate CYP1A2 inducers (e.g., Rifampicin, Omeprazole) is expected to decrease Riluzole exposure, which may affect efficacy. Smoking, categorized as a CYP1A2 inducer, is also documented as decreasing Riluzole plasma levels.

A key pharmacodynamic interaction involves an increased risk of hepatotoxicity. Official labels advise caution regarding co-administration with other hepatotoxic drugs (e.g., Allopurinol, Methyldopa) due to this potential for additive liver-related risk.

Regarding administration timing, the oral suspension formulation has a mandatory regulatory rule requiring it to be administered at least one hour before or two hours after a meal to prevent reduced absorption. Furthermore, use is not recommended for patients with pre-existing hepatic impairment, as documented in official labeling.

Regulating Glutamate and Neurotransmitter Balance

Rizol acts on the glutamatergic system by primarily inhibiting presynaptic voltage-gated sodium channels, thereby reducing the release of the excitatory neurotransmitter glutamate into the synapse. It further modulates the system by enhancing the function of astroglial transporters, such as GLT1, to increase glutamate reuptake and clearance. This combined action reduces overall synaptic glutamate levels and reduces the intensity of excitatory signaling.

️ Modulating the Excitotoxicity Cascade

By limiting sustained synaptic glutamate levels, Rizol alters the cascade of excitotoxicity, a process linked to calcium-mediated neuronal structural changes. This mechanism contributes to the maintenance of neuronal structure and function in the presence of glutamatergic overstimulation.

Modifying Neuronal Electrical Activity

The drug's activity on sodium channels, which are central to the action potential, results in the stabilization of the neuronal membrane potential. This electrophysiological effect reduces the frequency of spontaneous and rapid firing in high-activity circuits, thereby modulating the overall electrical activity within the central nervous system.

How Rizol is Used — Official Administration Guidelines

Rizol (Riluzole) is administered as a long-term, continuous supportive regimen, and its use is governed by a fixed, non-titrated dosage protocol. The standard regimen is 100 mg per day, delivered in two equal 50 mg portions.

---

Official Dosing and Frequency

Feature	Administration Protocol
Recommended Dose	50 mg unit dose, taken twice daily (every 12 hours).
Route of Administration	Oral use. The oral suspension form may also be administered via a Percutaneous Endoscopic Gastrostomy (PEG) tube.
Timing with Meals	Doses must be taken on an empty stomach, specifically at least 1 hour before or 2 hours after a meal.

---

Procedural Administration Constraints

The correct use of Rizol requires adherence to form-specific rules outlined in the prescribing information:

• Tablets must be swallowed whole and should not be broken, chewed, or crushed.
• Oral Suspension requires the bottle to be gently shaken for at least 30 seconds before the dose is measured and administered.
• Oral Film is placed on the tongue to dissolve and should not be cut, split, or taken with liquids; the patient must refrain from chewing while it dissolves.

Missed Dose: If a 50 mg dose is missed, it must be skipped, and the patient should resume the twice-daily schedule with the next regularly timed dose; double doses are not permitted.

Special Populations: The use of Rizol is not recommended for children. For older adults (aged 70 years and above), the recommended 100 mg daily dose remains unchanged, as no specific adjustment is required based on age.

Research Evidence / Overview of Studies for Rizol

---

Evidence for Use in Amyotrophic Lateral Sclerosis (ALS) / Motor Neuron Disease (MND)

The foundational understanding of Rizol's role was studied for in a series of Randomized Controlled Trials (RCTs). These pivotal studies were evaluated in adult patients diagnosed with Amyotrophic Lateral Sclerosis (ALS), comparing the medicine against a placebo. These trials are considered a high standard of evidence because they help researchers observe patterns in large groups of patients under controlled conditions. The RCT findings were further analyzed in several Systematic Reviews and Meta-analyses.

Examination of Survival and Disease Progression

The research primarily focused on two outcomes related to disease progression. The primary outcome was studied for survival time, defined as the time until death or the time until a patient required a tracheostomy. Research examined the measured survival time between the treated group and the placebo group. The findings describe patterns observed in the studies; the trials recorded measurements related to the median time to the survival endpoint.

Evidence on Functional and Motor Measures

Studies also examined outcomes reflecting daily functioning or activity level, especially regarding the impact of ALS on movement, speech, and swallowing. These functional measures were evaluated in the observed populations using standardized scales, such as the ALS Functional Rating Scale (ALSFRS-R).

Studies reported that the findings related to these functional measures were mixed. Research highlights changes measured during the study period, but the available data suggests that the difference measured on outcomes like muscle strength and overall motor function was limited and not statistically or clinically significant across all studies.

---

Long-Term Studies and Follow-up

While the initial regulatory decisions were based on intermediate-term RCTs, subsequent research has focused on longer observation periods. Observational Studies and Real-World Evidence (RWE) track outcomes in patient registries, providing data that extend beyond the typical 12-to-21-month duration of the initial clinical trials.

---

What Remains Uncertain About Rizol Research

Crucially, the research provides limited insight into the medicine's role in the rate of functional decline. Furthermore, the evidence base is restricted concerning patients who begin treatment immediately upon the earliest diagnosis. The follow-up durations were limited in the most rigorous placebo-controlled trials, meaning the full trajectory of the medicine's long-term effect is better understood through less-controlled observational data. Findings describe group patterns, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) - Cochrane Review
2. Clinical trials of riluzole in patients with ALS

Common questions about Rizol (FAQ)

Q: Does Rizol interact with common vitamins or dietary supplements?

Official information describes that Rizol is processed in the liver by a specific enzyme called CYP1A2. The regulatory document states that substances which strongly affect this enzyme, which could include certain supplements, may potentially alter the amount of Rizol in the body. Official sources indicate that patients should discuss the use of vitamins or supplements with a qualified healthcare professional.

Q: Are the side effects of Rizol usually mild or severe?

Official product information lists both frequently reported adverse reactions, such as weakness (asthenia) and nausea, as well as less common but clinically significant warnings. Serious adverse reactions described in the documentation include potential liver injury, a severe decrease in white blood cell count, and specific lung conditions. Official information describes the range of potential effects that patients should be aware of.

Q: Are there known interactions between Rizol and common pain relievers?

Regulatory documents advise caution when using Rizol alongside other medications known to be toxic to the liver. This warning is due to the potential for increased risk of liver-related toxicity (hepatotoxicity). Official sources describe the caution advised regarding co-administration of such medications.

Q: How long does Rizol stay in a person's system after they stop using it?

The elimination half-life of the active substance, Riluzole, is described in scientific documents as approximately 9 to 15 hours. The half-life describes the time it takes for the concentration of the medicine to drop by half. The concentration of the medicine in the body significantly decreases over several half-lives.

Q: Are there any known foods that interact with Rizol?

Official administration guidelines state that Rizol must be taken on an empty stomach for proper absorption. This means the dose should be taken at least one hour before or two hours after a meal. This administration requirement is intended to support the proper intake and absorption of the medicine.

Q: Does Rizol cause changes in mood or sleep patterns?

The regulatory product information lists dizziness and the risk of sleepiness as common adverse reactions. Due to the potential for these effects, official warnings describe that driving or operating heavy machinery is restricted if a person experiences dizziness or sleepiness. The information focuses primarily on effects on alertness and movement.

Q: Are there specific warnings related to Rizol and alcohol?

Official information indicates that alcohol consumption may intensify the liver-related risks associated with Rizol. Official information describes the recommendation to limit or reduce alcohol intake while using this medicine due to the increased potential for liver injury (hepatotoxicity).

Q: What are the possible signs of a serious, but rare, side effect of Rizol?

Official labels advise patients to promptly report certain signs that may indicate serious adverse reactions. These symptoms include any fever, a dry cough, difficulty breathing, or yellowing of the skin or eyes. These symptoms may require immediate medical evaluation and should be reported quickly as directed by official information.

Q: What is the half-life of Rizol as described in scientific documents?

The mean elimination half-life of Riluzole, the active substance in Rizol, is described in scientific documents as approximately 9 to 15 hours. This figure describes the time it takes for the concentration of the medicine to drop by half.

Q: Does Rizol interact with alcohol?

Official information indicates that alcohol consumption may intensify the liver-related risks associated with Rizol. Official information describes the recommendation to limit or reduce alcohol intake while using this medicine due to the increased potential for liver injury (hepatotoxicity).

Q: What is the overall safety profile of Rizol based on long-term data?

Observational research and Real-World Evidence (RWE) describe patterns suggesting that Rizol is generally well-tolerated over extended periods. This research suggests that most adverse events recorded during long-term use were often related to the progression of the underlying condition rather than the medication itself.

Q: How does the body break down and eliminate Rizol?

Rizol is primarily broken down, or metabolized, in the liver by a specific enzyme called CYP1A2. The drug is then primarily eliminated from the body through excretion via the urine. The official product information details how the body processes this medicine.

Q: Are there genetic factors that influence how a person responds to Rizol?

Regulatory text notes that there is high variability in how the body processes Rizol. This variability may be attributed to differences in the liver's CYP1A2 enzyme, which is responsible for breaking down the drug. Official documents note that individual differences may potentially affect how the drug is cleared from the body.

Q: Does Rizol have a black box warning?

Rizol does not have a formal Boxed Warning, sometimes called a Black Box Warning, on its label. However, the official labeling contains prominent warnings and precautions highlighting serious risks, such as potential hepatic injury and low white blood cell count.

How to Store and Dispose of Rizol (Riluzole)

The storage and disposal of Rizol (Riluzole) must align with official regulatory requirements to maintain product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Tablets must not be stored above 25 C; the oral suspension requires storage between 20 C and 25 C.
Protection	Store in the original package to protect the medicine from both light and moisture.
Handling	The oral suspension must not be frozen and should be shaken well before use.
Child Safety	The medicine must be kept out of the sight and reach of children.
Stability	The oral suspension must be used within 15 days of first opening the bottle, and any remaining product must be discarded after this period.

Disposal Instructions

Unused or expired Rizol must be disposed of according to local regulatory requirements. The medicine must not be thrown into household rubbish or flushed down wastewater.